Successes and challenges of leukaemia treatment using CAR-T cells – where are we now?
Treatment of leukaemia and lymphomas using genetically modified immune cells of the patient (CAR-T cells) has produced impressive results in clinical trials, especially for the treatment of B-cell malignancies. However, serious adverse events were reported as well, partly with fatal outcome.
Safe blood products world-wide: Successful collaboration of the Paul -Ehrlich-Institut with the World Health Organisation (WHO) to be continued
The "WHO Collaborating Centre for Blood Products and in vitro Diagnostic Devices" at the Paul-Ehrlich-Institut (PEI) started a collaboration with the World Health Organisation (WHO) as long ago as twelve years. Now, an extension of the collaboration has been confirmed for another four years. After the "WHO Collaboration Centre for Standardization and Evaluation of Vaccines", the second WHO Collaboration Centre at the PEI has been confirmed by the WHO.
Important role for activation of a membrane switch in immunity
Innate immune responses serve as rapid defence against pathogenic agents. In this context, specialised macrophages play an important role, which kill and break down the pathogen in vesicles within cells. The mechanism of these processes and how they are controlled has so far only partly been understood.